From: Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit
Phenobarbital (N = 37) | Ursodiol (N = 31) | p-value | |
---|---|---|---|
Gestational Age at Birth (%) | 0.7628 | ||
22–28 weeks | 38 | 45 | |
28–34 weeks | 40 | 32 | |
> 34 weeks | 22 | 23 | |
Male (%) | 57 | 71 | 0.2261 |
Race (%) | 0.1439 | ||
Caucasian | 58 | 61 | |
African American | 20 | 32 | |
Other | 22 | 7 | |
IUGR (%) | 19 | 32 | 0.2058 |
On Restricted Lipids at start of drug therapy (%) | 46 | 39 | 0.5479 |
Length of Drug Course a | 17 (13,38) | 17 (12,32) | 0.4557 |
Dose (mg/kg/day) a | 4.48 (3.84, 5.05) | 27.43 (22.39,29.00) | n/a |
Direct Bilirubin at start of drug therapy | 0.8458 | ||
mg/dLb | 7.1 (3.98) | 6.9 (4.92) | |
umol/L b | 121.1 (68.1) | 118.0 (84.2) |